Enara Bio

Enara Bio Limited, based in Oxford, United Kingdom, is a biotechnology company focused on developing innovative cancer immunotherapies.

Founded in November 2016, Enara Bio specializes in targeting unique cancer antigens known as Dark Antigens®, which are derived from non-coding regions of the genome. The company operates with a dedicated team of approximately 61 employees and has secured significant funding to advance its research and development efforts. Enara Bio utilizes two proprietary technology platforms: the EDAPT® platform for discovering Dark Antigens and the EnTiCE® platform for optimizing bispecific T-cell engagers. These platforms enable the development of targeted immunotherapies aimed at improving treatment outcomes for patients with solid tumors. The company's lead candidate, ENA101, is a bispecific T-cell engager that is progressing toward first-in-human clinical studies planned for early 2026. Enara Bio collaborates with leading pharmaceutical companies and research institutions to further its mission of transforming cancer treatment through the exploration of Dark Antigens.